Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models
21. Mai 2024 08:30 ET
|
Palisade Bio, Inc.
Data presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing...
Palisade Bio to Participate in the Virtual Investor Lunch Break Event
11. April 2024 09:15 ET
|
Palisade Bio, Inc.
– Live webcast with members of Palisade Bio management on Tuesday, April 16th at 12:00 PM ET Carlsbad, CA, April 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”,...